Immune-Modulating Vaccines in Non-small Cell Lung Cancer  by Nemunaitis, John & Murray, Nevin
TARGETED THERAPIES SUPPLEMENT
Immune-Modulating Vaccines in Non-small Cell Lung
Cancer
John Nemunaitis, MD,* and Nevin Murray, MD†
The limited efficacy and moderate toxicity of chemotherapy for
non-small cell lung cancer (NSCLC) have given the search for a
more effective and safer systemic treatment a sense of urgency.
NSCLC has historically been regarded as a non-immunogenic
cancer, and immunotherapy has yielded little benefit in humans.
However, encouraging clinical results in patients immunized
with novel vaccines directed toward enhancement of tumor
antigen recognition have been published. In this review, we
describe the scientific basis and updates the clinical results of
three vaccine approaches (GVAX, Lucanix, and L-BLP25) and
discuss preliminary work on a novel Ras mutation targeted
immune therapy. Further studies are needed to demonstrate
whether these novel therapies can potentially complement or
replace current therapeutic approaches.
(J Thorac Oncol. 2006;1: 756–761)
Much of the focus in immunotherapy has been in the areaof cancer vaccine development. A major objective of
this strategy is the ability to induce immune responses to
tumor-specific antigens that can be recognized by the immune
system, which will result in the differential elimination of
cells expressing such antigens. The critical components of a
cancer vaccine approach include identification of antigens
and an effective delivery system to therapeutically provide
the antigenic material.1 Three vaccines in particular have
advanced in clinical development for non-small cell lung
cancer (NSCLC). The first is an autologous tumor cell vac-
cine transfected with an adenoviral vector that delivers the
GM-CSF gene (GVAX). The next is an allogenic cell vaccine
transfected with a TGF2 antisense gene plasmid (Lucanix),
and the third is a MUC1 lipopeptide delivered as a liposome
vaccine called L-BLP25. These vaccines recently demon-
strated activity in clinical trial exemplifying these critical
components and will be discussed in this review. We review
updated clinical results of GVAX, Lucanix, and BLP25 and
discuss preliminary results of a novel Ras mutation targeted
immune therapy.
GVAX
A comparison involving multiple cytokine genes found
GM-CSF gene-transduced vaccines were potent inducers of
tumor immunity in animal models.2 Secretion of GM-CSF by
genetically modified tumor cells induces local tumor antigen
expression and stimulates cytokine release at the vaccine site,
which activates and attracts antigen-presenting cells, thereby
inducing a tumor-specific cellular immune response.3 Preclin-
ical studies conducted with GVAX have shown no significant
local or systemic toxicities at clinically relevant doses.2,4–6
Several phase I/II human trials using GM-CSF–secret-
ing autologous or allogeneic tumor cell vaccines have been
performed.7–12 We evaluated GVAX in a multicenter phase
I/II trial involving patients with early-stage and advanced-
stage NSCLC. For vaccine preparation, tumor tissue was
obtained surgically or by thoracentesis in the case of malig-
nant effusions. Cells were exposed overnight to vector super-
natant (Ad-GM). The Ad-GM is a replication-defective vec-
tor constructed by replacing the E1 gene of adenovirus type
5 with the gene for human GM-CSF and deleting an addi-
tional segment in the E3 region.13 Cells were irradiated at
10,000 cGY and cryopreserved in preparation for treatment.
GVAX was administered intradermally every 2 weeks for a
total of six vaccinations. The vaccine dose was individualized
on the basis of yield, and each dose contained 5  106 to 100
 106 tumor cells. Forty-three patients with NSCLC (10 early
stage, 33 late stage) were vaccinated. The most common
vaccine-related adverse events were local vaccine injection
site reactions (93%), followed by fatigue (16%) and nausea
(12%). Of the 33 patients, five induced serum antibodies
reactive against autologous tumors after vaccination. Of the
41 patients, 32 (78%) demonstrated antibody reactivity
against at least one of seven allogenic NSCLC cell lines. No
statistically significant differences in immune function were
noted between the patients with early- and advanced-stage
disease. Three patients with advanced-stage disease achieved
durable, complete tumor regressions (Figure 1). Two remain
without disease almost 5 years after vaccine. Both had failed
prior front line and second-line therapy before vaccination
and had multi-site disease involvement including brain, lung,
lymph nodes, and bone. The complete responses occurred at
doses of 6.7  106 to 10  106 tumor cells per vaccine and
at vaccine GM-CSF secretion rates of 44 to 236 ng/day per
106 cells. One complete responder showed an in vitro T-cell
response to autologous tumor-pulsed dendritic cells after
vaccination. The overall median progression-free survival of
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the patients with advanced-stage disease was 4 months, and
the medial overall survival was 12 months. Survival at 1 year
was 44%. Vaccine-associated GM-CSF secretion was signif-
icantly associated with survival. Medial survival among pa-
tients receiving vaccines secreting GM-CSF at a rate of at
least 40 ng/day per 106 cells was 17 months compared with 7
months for those receiving vaccines secreting less GM-CSF
(P  0.028).
In an effort to remove the requirement for genetic
transduction of individual tumors, to optimize GM-CSF
transgene expression, given that this correlated with im-
proved survival as described in our earlier results, we worked
with Cell Genesys (San Francisco, CA) in the development of
a second approach called “bystander” GVAX, which is a
platform composed of autologous tumor cells mixed with an
allogeneic GM-CSF–secreting cell line (K562 cells).14 We
conducted a phase I/II trial of this vaccine (3 to 12 biweekly
vaccinations) in advanced-stage NSCLC.15 Tumors were har-
vested from 86 patients, tumor cell processing was successful
in 76, and 49 proceeded to vaccination. Serum GM-CSF
pharmacokinetics were consistent with secretion of GM-CSF
from vaccine cells for up to 4 days, with associated transient
leukocytosis confirming the bioactivity of vaccine-secreted
GM-CSF. Evidence of vaccine-induced immune activation
was demonstrated; however, objective tumor responses were
not seen. Compared with autologous GVAX vaccines pre-
pared by transduction of individual tumors with an adenoviral
GM-CSF vector, vaccine GM-CSF secretion was approxi-
mately 25-fold higher with the bystander GVAX vaccine
used in this trial. However, the frequency of vaccine site
reactions, tumor response, time to disease progression, and
survival were all less favorable in that efficacy was similar to
standard therapy of second-line treated NSCLC. We conclude
that autologous malignant tissue transfection with Ad GM-
CSF, despite variability of GM-CSF expression levels and
cell dynamics, is optimal.
LUCANIX
In an effort to minimize processing limitations with
GVAX and the necessity of surgical procedures for vaccine
tissue acquisition, we designed an alternative vaccine plat-
FIGURE 1. Complete tumor re-
sponse to GVAX as shown by ra-
diologic assessment. (A-D), Patient
1. (A and B), Baseline tumor stag-
ing showing two lung tumors, one
of which (B) was resected for vac-
cine processing. (C and D), Com-
plete tumor regression after GVAX
vaccination. (E-H), Patient 2. (E and
F), Baseline tumor staging showing
two lung lesions, one of which (E)
was resected. (G and H), Complete
tumor regression after vaccination.
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form called Lucanix-NSCLC. Lucanix is a non-viral gene-
based allogeneic vaccine that incorporates TGF-2 antisense
gene modification of a cocktail of four different NSCLC cell
lines. Increased levels of TGF-2 are linked to immunosup-
pression in patients with cancer,16–21 and the level of TGF-2
is inversely correlated with prognosis in patients with
NSCLC.22 TGF-2 has antagonistic effects on natural killer
cells, lymphokine-activated killer cells, and dendritic
cells.23–28 Using an antisense (AS) gene to inhibit TGF-2,
several have demonstrated inhibition of cellular TGF-2
expression with resultant increased immunogenicity of gene-
modified cancer cells.29–37
In a recent phase II study involving 75 patients with
early-stage (n  14) and late-stage NSCLC (n  61), we
defined a dose-related effect of Lucanix 38. Patients were
randomized to one of three dose cohorts (1.25  107, 2.5 
107, or 5 107 cells/injection). We found no adverse toxicity
and an impressive survival advantage at dose levels 2.5 
107 cells/injection, with an estimated 2-year survival of 47%
in response to Lucanix in 41 patients with advanced-stage
disease (IIIB, IV) (Figure 2). This compared favorably with
the historical 2-year survival rate of less than 20% of patients
with stage IIIB/IV NSCLC.39–44 Furthermore, a correlation
of positive outcome with induction of immune enhancement
of tumor antigen recognition was observed. Immune function
was explored in the 61 patients with advanced-stage disease
(IIIB/IV). Cytokine production (IFN-, P 0.006; IL-6, P
0.004; IL4, P  0.007) was induced, antibody-mediated
response to vaccine HLA antigen was observed (P  0.014),
and cell-mediated response showed a correlation trend (P 
0.086) in patients achieving stable disease or better. We
conclude that further phase III investigation of Lucanix is
justified and warranted. Trial design will likely include com-
parison of second-line stage IIIB/IV patients with NSCLC
randomized to Alimta (pemetrexed) or Lucanix. Currently we
are exploring the relationship of circulating tumor cells and
vaccine response in a second phase II trial.
L-BLP25
MUC1 is a high molecular weight protein containing
large amounts of O-linked sugars and is expressed on the
apical borders of most normal secretory epithelial cells.45 In
many cancers, MUC1 is over-expressed, under- or aberrantly
glycosylated, and expressed over the whole cell surface of
tumor cells.46 These characteristics make the tumor-associ-
ated MUC1 antigenically distinct from normal MUC1. The
MUC1 protein consists of a transmembrane domain, a cyto-
plasmic domain, and an extracellular domain consisting
largely of a tandemly repeating sequence of 20 amino acids
that are O-glycosylated.47 Recent studies have identified that
MUC1 is associated with cellular transformation as demon-
strated by tumorigenicity48 and can confer resistance to geno-
toxic agents.49 High-level cell surface expression,50 reported
immunosuppressive activities of its released ectodomain,51
and anti-adhesive properties all contribute to the ability of
this mucin to protect and promote tumor cell growth and
survival and make MUC1 an attractive target for cancer
immunotherapy.
Both the oligosaccharide portion and the tandem repeat
of the MUC extracellular domain have potential for immu-
notherapeutic activity. The L-BLP25 vaccine consists of a
lipopeptide that is slightly larger than one tandem repeat of
the MUC1 backbone, and an immunoadjuvant, monophos-
phoryl lipid A (MPLA), in a liposomal formulation. L-BLP25
vaccine has been tested in three NSCLC trials (n  43 total)
and a single 16-patient prostate cancer trial.52 Three doses
and two regimens were tested, including one regimen using
liposomal IL-2 as an adjuvant. In these studies, L-BLP25
vaccine induced MUC1-specific T-cell responses and gener-
ated interesting survival observations.
Recently, results of a phase IIIB study of L-BLP-25 in
advanced-stage NSCLC were updated. Patients with ECOG 0
to 2, stable or responding stage IIIB or IV NSCLC after any
standard first-line chemotherapy were pre-stratified by stage
and randomized to either L-BLP25 plus best supportive care
(BSC) (88 patients) or BSC alone (83 patients). Patients in
the L-BLP25 arm received a single intravenous dose of
cyclophosphamide 300 mg/m2 followed by eight weekly
subcutaneous immunizations with L-BLP25 (1000 g).
Maintenance immunizations were given at 6-week intervals.
One hundred seventy-one patients were enrolled be-
tween August 2000 and September 2002.53 The overall sur-
vival results indicate a 4.4-month longer median survival for
patients in the L-BLP25 arm (17.4 versus 13 months), which
did not reach statistical significance (P  0.112 Cox). In
subset analyses, 106 had pleural effusion-positive IIIB or
stage IV disease. These patients did not benefit from the
treatment, and the survival curves overlap. In a stratified
subset of 65 locoregional IIIB disease, 35 were randomized to
vaccine and 30 to BSC. The median survival for vaccine
patients in the IIIB locoregional subset (Figure 3) was 30
months versus 13.3 months for the BSC control arm (P 
0.09; hazard ratio 0.56 [0.29, 1.1]). There were no major
toxicities. Quality of life (QoL) results indicated QoL was
maintained longer in patients in the L-BLP25 arm.
The clinically meaningful survival advantages seen for
patients with stage IIIB NSCLC treated with L-BLP25 is
encouraging. A phase III randomized trial of BLP-25 versus
FIGURE 2. Overall survival for cohorts 1 versus 2 and 3 for
patients with advanced-stage disease who received Lucanix
(n  61, P 0.0186)
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control for patients with unresectable stage III NSCLC with
response or stable disease after chemoradiation is planned.
RAS-TARGETED, WHOLE YEAST-BASED
IMMUNOTHERAPY
Activating mutations in Ras oncoproteins represent
attractive targets for cancer immunotherapy, but few vectors
capable of generating immune responses required for tumor
killing without vector neutralization have been described.
Administration of intact baker’s yeast, Saccharomyces cer-
evisiae, engineered to produce recombinant antigens present
in tumor targets provoke cell-mediated immune responses.
Yeast is avidly taken up by dendritic dells and macro-
phages.54 Lu et al.55 used a model of urethane-induced lung
tumors in A/J mice that harbor Ras codon 61 mutations. In
this model, hyperplasias appear in the lung 2 to 3 weeks after
urethane exposure, and microscopically visible adenomas are
evident after 5 weeks. By 10 months, adenocarcinomas oc-
cupy a whole lung lobe, and by 12 months the mice die from
respiratory distress. Therapeutic immunization with the
whole recombinant yeast caused complete regression of es-
tablished Ras mutation-bearing lung tumors in a dose-depen-
dent, antigen-specific manner.
Mutated Ras is an obvious target in NSCLC, particu-
larly because tumors with mutated Ras are difficult to treat.
Tarmogen (targeted molecular immunogen) technology in-
volves creation of yeast vaccines transfected with plasmids
for the three most common Ras mutations. In an ongoing
phase I study in patients with pancreas and lung cancer, no
serious adverse events have been reported. A phase II study
in advanced NSCLC is planned.
CONCLUSION
Historically, NSCLC has generally been regarded as a
non-immunogenic cancer.56 Immunotherapy for lung cancer
has yielded little benefit in humans;57–59 however, prelimi-
nary results of vaccine studies, as described herein, which are
designed to enhance tumor antigen recognition have demon-
strated beneficial outcome in subsets of patients with
NSCLC.11,12,60–62
Hypotheses as to why previous immune approaches to
NSCLC have yielded disappointing results include ineffec-
tive priming of tumor specific T-cells, lack of high validity
tumor-specific T-cells, and physical or functional disabling of
primed tumor-specific T-cells by primary host and/or tumor-
related mechanisms. Based on results demonstrated herein
and by others,61,63–65 one could hypothesize that approaches
that lead to enhancement of activation of effector cells may
provide clinically relevant activity in subsets of patients.
Recent demonstration of several dramatic responses with
“priming” vaccine approaches are consistent with this expla-
nation. In view of an acceptable safety profile and suggestive
survival advantage, further investigation of each of these
approaches is recommended.
L-BLP25 and Lucanix are about to undergo phase III
investigation in NSCLC. Analysis of gene expression pat-
terns of cancer tissue using cDNA microarray assessment are
being studied and may provide signals with respect to respon-
sive and unresponsive disease. Monitoring of circulating
cancer cells based on cytokeratin expression recently dem-
onstrating pragmatic significance in patients with advanced-
stage breast cancer is an interesting area of investigation and
may be useful in monitoring the duration of vaccine response.
Attraction to further definitive clinical investigation of
vaccines that enhance tumor antigen recognition in patients
with late-stage NSCLC is derived not only from the sugges-
tion of a modest survival impact, but also the remarkably low
toxicity profile; however, excitement over immunotherapy
approaches in NSCLC await completion of phase III trials.
FIGURE 3. Survival analysis for
patients with stage IIIB locoregional
disease in the phase IIB trial of
BLP25 liposome vaccine.
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